Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Status:
Completed
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of
CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive
sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice
daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The
Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each
session. Hair loss was calculated from SALT score at presentation and on follow-up after 3
months. The degree of response was assessed on the basis of hair re-growth as excellent (>75%
re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25%
re-growth). To determine statistical significance χ2-square test, taking p-value <0.05 as
significant, was used.